Combination therapy for platinum-resistant ovarian cancer: a novel at-home regimen with envafolimab, lenvatinib, and etoposide
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf210 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift The Oncologist, 2025. Verfasst von Bo Ding und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Etoposide, Ovarian Neoplasms, Phenylurea Compounds. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Effective and tolerable treatment for patients with platinum-resistant recurrent ovarian cancer remains a great challenge in clinical practice. This study aimed to evaluate the efficacy and safety of envafolimab, the first subcutaneously administered programmed death ligand 1 (PD-L1) inhibitor, combined with lenvatinib and etoposide in patients with platinum-resistant recurrent ovarian cancer.
Methods
This was an open-label, single-arm, phase 2 trial (ENLEN-OC-001). Patients with platinum-resistant recurrent ovarian cancer were eligible for inclusion who were administered envafolimab subcutaneously on day 1 and lenvatinib and etoposide orally on days 1-14, with 21 days as a cycle. After 6-10 cycles, envafolimab and lenvatinib were taken as maintenance therapy until intolerable toxicity, disease progression, withdrawal of consent, or finishing 24 months of treatment. The primary endpoint was objective response rate (ORR), and the secondary endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety.
Results
Of the screened 28 patients, 21 were included, with 18 being assessed for the efficacy and safety. The ORR was 44.4% (95% CI 21.5%-69.2%), and the DCR was 83.3% (95% CI 58.6%-96.4%). The median PFS was 10.2 months (95% CI 5.6-not applicable [NA]), and the median OS was 21.3 months (95% CI 6.8-NA). The most common grade 3/4 adverse events were leukopenia (27.8%) and thrombocytopenia (16.7%). No serious adverse events or treatment-related deaths were reported. No changes were observed in the depression, anxiety, and quality of life following treatment.
Conclusion
Envafolimab combined with lenvatinib and etoposide showed promising efficacy and tolerable safety for patients with platinum-resistant recurrent ovarian cancer. ClinicalTrials.gov identifier NCT05422183
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.
- Nanjing Key Laboratory of Intelligent Obstetrics and Gynecology Medicine, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.
- Department of Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.
- Department of Clinical Science and Research, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.
- State Key Laboratory of Neurology and Oncology Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing Simcere Medical Laboratory Science Co., Ltd, Nanjing 210042, China.
- Department of General Practice, Zhongda Hospital, Institute of Diabetes, School of Medicine, Southeast University, Nanjing 210009, China.
ORCID-Profile: Yang Shen
Zitieren
APA
Ding, B., Yu, T., Zheng, S., Xu, J., Ji, F., Lin, H., Zhao, X., Qiu, S., & Shen, Y. (2025). Combination therapy for platinum-resistant ovarian cancer: a novel at-home regimen with envafolimab, lenvatinib, and etoposide. The Oncologist. https://doi.org/10.1093/oncolo/oyaf210
Vancouver
Ding B, Yu T, Zheng S, Xu J, Ji F, Lin H, et al. Combination therapy for platinum-resistant ovarian cancer: a novel at-home regimen with envafolimab, lenvatinib, and etoposide. The Oncologist. 2025. doi:10.1093/oncolo/oyaf210
BibTeX
@article{Ding2025,
author = {Ding, Bo and Yu, Tianxiang and Zheng, Shiya and Xu, Jingyun and Ji, Feng and Lin, Hao and Zhao, Xiang and Qiu, Shanhu and Shen, Yang},
title = {Combination therapy for platinum-resistant ovarian cancer: a novel at-home regimen with envafolimab, lenvatinib, and etoposide},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf210}
}
EUVIMED